Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Medtech is seeing new exciting developments in the field of medical diagnostics, with recent innovations allowing for faster disease diagnosis than ever before. We cover 10 diagnostic tests that could change how quickly we can catch dangerous diseases. Read more
Robotic surgery is taking off, and the field is becoming increasingly diverse – here’s the latest news from innovations in the new and growing medtech field. Read more
NeoTract today presented 5-year results from the pivotal Lift IDE study of its UroLift system, touting rapid reduction of symptoms and sustained effects in treating patients with symptomatic benign prostatic hyperplasia.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. Read more
The recent WannaCry ransomware attack which hit international healthcare facilities has had some impact on the US healthcare systems and certain medical devices, according to the Department of Health & Human Services.
The HHS organized a conference call on Monday with US health organizations to address the issue and said that certain medical devices had become infected with the malware, according to a Fox Business report. Read more
Xeltis today released early data on its bioresorbable heart valves built on endogenous tissue restoration technology, touting potential benefits of the regenerative approach to heart valve replacement.
The Swiss medical device company’s technology is designed to promote endogenous tissue restoration using polymers structured as a resorbable “porous matrix.” The aim is to gradually replace the polymer structure with naturally regrown tissue, and the company is currently testing the system in pulmonary and aortic valves. Read more